• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

放射治疗的成本评估:我们了解什么?一项欧洲放射肿瘤学会-健康经济研究优化组织分析。

Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis.

作者信息

Defourny Noémie, Dunscombe Peter, Perrier Lionel, Grau Cai, Lievens Yolande

机构信息

European Society for Radiotherapy and Oncology, Brussels, Belgium.

University of Calgary, Calgary, Canada.

出版信息

Radiother Oncol. 2016 Dec;121(3):468-474. doi: 10.1016/j.radonc.2016.12.002.

DOI:10.1016/j.radonc.2016.12.002
PMID:28007378
Abstract

Although economic evidence is becoming mandatory to support health care decision-making, challenges remain in generating high quality cost data, especially for complex and rapidly evolving treatment modalities, such as radiotherapy. The overall aim of this systematic literature review was to critically analyse the type and quality of radiotherapy cost information available in cost calculation studies, from the health care provider's perspective, published since 1981. A selection process, based on strict and explicit criteria, yielded 52 articles. In spite of meeting our criteria these studies displayed large heterogeneity in scope, costing method, inputs and outputs. The limited use of conventional costing methodologies along with insufficient information on resource inputs hampered comparability across studies. A consistent picture of radiotherapy costs, based on methodologically sound costing studies, has yet to emerge. These results call for developing a well-defined and generally accepted cost methodology for performing economic evaluation studies in radiotherapy.

摘要

尽管经济证据对于支持医疗保健决策已变得不可或缺,但在生成高质量成本数据方面仍存在挑战,尤其是对于复杂且迅速发展的治疗方式,如放射治疗。本系统文献综述的总体目标是,从医疗保健提供者的角度,批判性地分析自1981年以来发表的成本计算研究中可用的放射治疗成本信息的类型和质量。基于严格且明确的标准进行的筛选过程产生了52篇文章。尽管符合我们的标准,但这些研究在范围、成本计算方法、投入和产出方面表现出很大的异质性。传统成本计算方法的使用有限,以及资源投入信息不足,阻碍了各项研究之间的可比性。基于方法合理的成本计算研究得出的放射治疗成本的一致情况尚未出现。这些结果呼吁开发一种明确且普遍接受的成本计算方法,用于进行放射治疗的经济评估研究。

相似文献

1
Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis.放射治疗的成本评估:我们了解什么?一项欧洲放射肿瘤学会-健康经济研究优化组织分析。
Radiother Oncol. 2016 Dec;121(3):468-474. doi: 10.1016/j.radonc.2016.12.002.
2
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
3
What is the value of routinely testing full blood count, electrolytes and urea, and pulmonary function tests before elective surgery in patients with no apparent clinical indication and in subgroups of patients with common comorbidities: a systematic review of the clinical and cost-effective literature.在没有明显临床指征的患者和常见合并症患者亚组中,在择期手术前常规检测全血细胞计数、电解质和尿素以及肺功能测试的价值:对临床和成本效益文献的系统评价。
Health Technol Assess. 2012 Dec;16(50):i-xvi, 1-159. doi: 10.3310/hta16500.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
5
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
6
Intravenous magnesium sulphate and sotalol for prevention of atrial fibrillation after coronary artery bypass surgery: a systematic review and economic evaluation.静脉注射硫酸镁和索他洛尔预防冠状动脉搭桥术后房颤:系统评价与经济学评估
Health Technol Assess. 2008 Jun;12(28):iii-iv, ix-95. doi: 10.3310/hta12280.
7
Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.将成本效益、可负担性和资源影响因素纳入指南制定中:COPD 指南制定中整合和协调工作的第 6 条。美国胸科学会/欧洲呼吸学会官方研讨会报告。
Proc Am Thorac Soc. 2012 Dec;9(5):251-5. doi: 10.1513/pats.201208-059ST.
8
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理:一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.
9
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.欧洲癌症研究与治疗组织(EORTC)癌症贫血患者促红细胞生成蛋白使用指南:2006年更新版
Eur J Cancer. 2007 Jan;43(2):258-70. doi: 10.1016/j.ejca.2006.10.014. Epub 2006 Dec 19.
10
The clinical effectiveness and cost-effectiveness of home-based, nurse-led health promotion for older people: a systematic review.基于家庭的、由护士主导的老年人健康促进的临床效果和成本效益:系统评价。
Health Technol Assess. 2012;16(20):1-72. doi: 10.3310/hta16200.

引用本文的文献

1
Cost-Outcome of Radiotherapy for Local Control and Overall Survival Outcomes for Selected Cancers.局部控制和特定癌症总体生存结局的放射治疗成本效益分析
J Med Imaging Radiat Oncol. 2025 Sep;69(6):641-648. doi: 10.1111/1754-9485.70000. Epub 2025 Aug 5.
2
Challenges in assessing national radiotherapy costs: application of the ESTRO-HERO model in Spain.评估国家放射治疗成本面临的挑战:ESTRO-HERO模型在西班牙的应用
Front Public Health. 2024 Dec 19;12:1474376. doi: 10.3389/fpubh.2024.1474376. eCollection 2024.
3
Quantifying societal burden of radiation-induced small bowel toxicity in patients with rectal cancer.
量化直肠癌患者放射性小肠毒性的社会负担。
Front Oncol. 2024 Jul 8;14:1340081. doi: 10.3389/fonc.2024.1340081. eCollection 2024.
4
Cost analysis of three-dimensional radiation therapy versus intensity-modulated chemoradiotherapy for locally advanced cervical cancer in Peruvian citizens.秘鲁公民局部晚期宫颈癌三维放射治疗与调强放化疗的成本分析
Ecancermedicalscience. 2023 Apr 20;17:1531. doi: 10.3332/ecancer.2023.1531. eCollection 2023.
5
Measuring Global Inequity in Radiation Therapy: Resource Deficits in Low- and Middle-Income Countries Without Radiation Therapy Facilities.衡量放射治疗领域的全球不平等现象:缺乏放射治疗设施的低收入和中等收入国家的资源短缺情况。
Adv Radiat Oncol. 2023 Mar 1;8(4):101175. doi: 10.1016/j.adro.2023.101175. eCollection 2023 Jul-Aug.
6
Adaptive radiotherapy for breast cancer.乳腺癌的自适应放射治疗。
Clin Transl Radiat Oncol. 2022 Dec 22;39:100564. doi: 10.1016/j.ctro.2022.100564. eCollection 2023 Mar.
7
Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.癌症相关医疗保健的经济学研究:综述文献概述
J Natl Cancer Inst Monogr. 2022 Jul 5;2022(59):12-20. doi: 10.1093/jncimonographs/lgac011.
8
A new therapeutic approach for bone metastasis in colorectal cancer: intratumoral melittin.一种用于结直肠癌骨转移的新治疗方法:瘤内注射蜂毒肽。
J Venom Anim Toxins Incl Trop Dis. 2022 Mar 14;28:e20210067. doi: 10.1590/1678-9199-JVATITD-2021-0067. eCollection 2022.
9
Cost and Toxicity Comparisons of Two IMRT Techniques for Prostate Cancer: A Micro-Costing Study and Weighted Propensity Score Analysis Based on a Prospective Study.两种用于前列腺癌的调强放射治疗技术的成本与毒性比较:一项基于前瞻性研究的微观成本分析和加权倾向评分分析
Front Oncol. 2022 Jan 11;11:781121. doi: 10.3389/fonc.2021.781121. eCollection 2021.
10
Clinical experience and cost evaluation of magnetic resonance imaging -only workflow in radiation therapy planning of prostate cancer.前列腺癌放射治疗计划中仅使用磁共振成像工作流程的临床经验与成本评估
Phys Imaging Radiat Oncol. 2021 Jul 17;19:66-71. doi: 10.1016/j.phro.2021.07.004. eCollection 2021 Jul.